RESEARCH TRIANGLE PARK, N.C. and EXTON, Pa., June 13, 2018 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc.
(“BioCryst”) (NASDAQ:BCRX), and Idera Pharmaceuticals, Inc. (“Idera”) (NASDAQ:IDRA), today announced that they will be presenting
at the JMP Securities Life Sciences Conference on Thursday, June 21, 2018 at 10:00 A.M. E.T.
Links to a live audio webcast and replay of this presentation may be accessed in the Investors section of
BioCryst’s website at http://www.biocryst.com and in the Investors and Media section of Idera’s website at http://www.iderapharma.com.
About BioCryst
BioCryst Pharmaceuticals designs, optimizes and develops novel small-molecule medicines that address both common
and rare conditions. BioCryst has several ongoing development programs including BCX7353, an oral treatment for hereditary
angioedema, galidesivir, a potential treatment for filoviruses, and a preclinical program to develop oral Alk-2 inhibitors for the
treatment of fibrodysplasia ossificans progressive (“FOP”). RAPIVAB® (peramivir injection), a viral neuraminidase
inhibitor for the treatment of influenza, is BioCryst's first approved product and has received regulatory approval in the U.S.,
Canada, Australia, Japan, Taiwan, Korea and the European Union. Post-marketing commitments for RAPIVAB are ongoing. For more
information, please visit the Company's website at http://www.biocryst.com.
About Idera
Harnessing the approach of the earliest researchers in immunotherapy and the company’s vast experience in developing proprietary
immunology platforms, Idera’s lead development program is focused on priming the immune system to play a more powerful role in
fighting cancer, ultimately increasing the number of people who can benefit from immunotherapy. Idera continues to invest in
research and development, and is committed to working with investigators and partners who share the common goal of addressing the
unmet needs of patients suffering from rare, life-threatening diseases. To learn more about Idera, visit www.iderapharma.com.
This press release contains forward-looking statements, including statements regarding future results and achievements. These
statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or
achievements to be materially different from any future results, performances or achievements expressed or implied by the
forward-looking statements. Please refer to the documents periodically filed by both BioCryst and Idera with the Securities and
Exchange Commission.
BCRXW
Investor Contacts:
For BioCryst
Thomas Staab
Senior Vice President, Chief Financial Officer
BioCryst Pharmaceuticals
Office: 919-859-7910
tstaab@biocryst.com
For Idera
Robert Doody
Vice President, Investor Relations and Corporate Communications
Idera Pharmaceuticals
Office: 617-679-5515
Mobile: 484‐639‐7235
rdoody@iderapharma.com
